Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Acinetobacter Infections Clinical Trials Pipeline Analysis: 25+ Companies are Working to Improve the Treatment Space | DelveInsight

Published

on

<!– Name:DistributionId Value:8745059 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1204938 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:52218178-caf2-40ce-a493-038a46032d29 –>

New York, USA, Feb. 08, 2023 (GLOBE NEWSWIRE) — Acinetobacter Infections Clinical Trials Pipeline Analysis: 25+ Companies are Working to Improve the Treatment Space | DelveInsight

Increasing incidence rate of hospital-acquired bacterial infections and the introduction of novel therapeutics that are safe and highly effective are the primary factors that are driving the market growth. This has led several companies to develop innovative therapies for the treatment of Acinetobacter Infections, including Entasis Therapeutics, Qpex Therapeutics, Brii Biosciences, Aridis Pharmaceuticals, VenatoRx Pharmaceuticals, Spero Therapeutics, and several others.

DelveInsight’s Acinetobacter Infections Pipeline Insight – 2023 report provides comprehensive global coverage of available, marketed, and pipeline Acinetobacter infections therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Acinetobacter infections pipeline domain.

Key Takeaways from the Acinetobacter Infections Pipeline Report

  • DelveInsight’s Acinetobacter infections pipeline report depicts a robust space with 25+ active players working to develop 27+ pipeline therapies for Acinetobacter infections treatment. 
  • Key Acinetobacter infections companies such as Entasis Therapeutics, Spero Therapeutics, Omnix Medical, ABAC Therapeutics, Venatorx Pharmaceuticals, TAXIS Pharmaceutical, Vaxdyn, ContraFect Corporation (CFRX), Debiopharm, Idorsia, Telum Therapeutics, Bioharmony Therapeutics, Destiny Pharma, BioVersys, Hoffmann-La Roche, SuperTrans Medical, Agile Biotics, Qpex Biopharma, Antabio, Nosopharm, Aridis Pharmaceuticals, Brii Biosciences, and others are evaluating novel Acinetobacter infections drug candidates to improve the treatment landscape.
  • Promising Acinetobacter infections pipeline therapies in various stages of development include Sulbactam-durlobactam, SPR206, OMN 7, ESKAPE Pathogens bacteriophages, TP-102, VNRX-5113, VXD-001, Debio1454, TP-6076, BH02, XF-73, BV100, AcinetoVax, RG6006, ​OMNIvance, PBP inhibitors, NOSO-2G, AR-401,  BRII-693, and others.
  • In December 2022, Brii Biosciences Limited announced progress against its strategic clinical development priorities, including various updates across its pipeline of infectious disease and central nervous system disease candidates. BRII-693 has a highly differentiated safety and efficacy profile to address the most difficult-to-treat Acinetobacter baumannii and Pseudomonas aeruginosa infections resistant to carbapenem. Brii Bio plans to submit a pre-IND to the China NMPA in the first quarter of 2023.
  • In November 2022, Innoviva, Inc. announced that the US Food and Drug Administration (FDA) accepted for Priority Review the new drug application (NDA) for SUL-DUR, an investigational drug for the treatment of infections caused by Acinetobacter baumannii-calcoaceticus complex (ABC), including multi-drug resistant and carbapenem-resistant strains. The Agency is currently planning to hold an advisory committee meeting to discuss this application. The target PDUFA date (or action date) is May 29, 2023.
  • In June 2022, BioVersys AG, announced that it had raised CHF 24.2 million in the first closing of its Series C round. This first closing was significantly oversubscribed by both existing and new investors from diverse geographies. BioVersys intends to complete the Series C investment round by the end of 2022. The company will use the investment to initiate first Phase II clinical trials of BV100 and BVL-GSK098 and the preclinical development of BV200. BV100 addresses serious infections caused by Carbapenem-Resistant Acinetobacter baumannii (CRAB) in hospitalized patients, where mortality currently reaches 50% while BVL-GSK098 targets the 10 million tuberculosis (TB) sufferers identified each year, of which 1.5 million die every year.
  • Debiopharm is developing Debio 1454, a FabI inhibitor targeting a combination of enteric bacteria species, A. baumannii, Enterobacter Spp., Klebsiella pneumoniae and E.coli. This compound belongs to a family of narrow-spectrum antiobiotics that combines a very potent activity on pathogens of interest while reducing the selective pressure on other bacterial strains and sparing the microbiome.

Request a sample and discover the recent advances in Acinetobacter infections treatment drugs @ Acinetobacter Infections Pipeline Report

The Acinetobacter infections pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Acinetobacter infections products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Acinetobacter infections pipeline landscape.

Acinetobacter Infections Overview

Acinetobacters are gram-negative aerobic bacilli or coccobacilli in the Moraxellaceae family. They are common and can survive on dry surfaces for up to a month, and they are frequently carried on the skin of healthcare workers, increasing the likelihood of patients being colonized and medical equipment being contaminated. Acinetobacter species are numerous; all can cause human disease, but Acinetobacter baumannii accounts for approximately 80% of infections. Acinetobacter colonizes easily at tracheostomy sites and can cause community-acquired bronchiolitis and tracheobronchitis in healthy children and tracheobronchitis in immunocompromised adults. Acinetobacter pneumonias acquired in hospitals are frequently multilobar and complicated. Secondary bacteremia and septic shock both have poor prognoses.

Infections caused by antibiotic-resistant bacteria Acinetobacter isolates may be treated with broad-spectrum cephalosporins (ceftazidime or cefepime), piperacillin-tazobactam, ampicillin-sulbactam, carbapenems (e.g., meropenem or imipenem-cilastatin), and fluoroquinolones as first-line therapy (e.g., ciprofloxacin). Aminoglycosides and trimethoprim-sulfamethoxazole are also effective first-line treatments for urinary tract infections.

Find out more about therapy for Acinetobacter infections @ Acinetobacter Infections Treatment Drugs

A snapshot of the Acinetobacter Infections Pipeline Drugs mentioned in the report:

Drugs Company Phase  MoA RoA
Sulbactam-durlobactam Entasis Therapeutics Pre-registration Beta lactamase inhibitors Intravenous
OMNIvance Qpex Biopharma Phase I Beta lactamase inhibitors Intravenous
XF-73 Destiny Pharma Preclinical Cell membrane permeability modulators NA
Debio1454 Debiopharm Preclinical Enoyl-ACP reductase inhibitors Intravenous
PBP-539 VenatoRx Pharmaceuticals Preclinical Penicillin-binding protein inhibitors NA
SPR 206 Spero Therapeutics Preclinical Bacterial outer membrane protein modulators; Cell wall inhibitors Intravenous
Gram negative lysisns ContraFect Corporatio Discovery Cell wall inhibitors NA

Learn more about the emerging drugs to treat Acinetobacter infections @ Acinetobacter Infections Clinical Trials

Acinetobacter Infections Therapeutics Assessment

The Acinetobacter infections pipeline report proffers an integral view of the Acinetobacter infections emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Acinetobacter Infections Pipeline Report 

  • Coverage: Global 
  • Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravitreal, Subretinal, Topical
  • Therapeutics Assessment By Molecule Type: Monoclonal antibody, Peptides, Polymer, Small molecule, Gene therapy
  • Therapeutics Assessment By Mechanism of Action: Beta lactamase inhibitors, Cell membrane permeability modulators, Enoyl-ACP reductase inhibitors, Penicillin-binding protein inhibitors, Bacterial outer membrane protein modulators; Cell wall inhibitors, Cell wall inhibitors
  • Key Acinetobacter Infections Companies: Entasis Therapeutics, Spero Therapeutics, Omnix Medical, ABAC Therapeutics, Venatorx Pharmaceuticals, TAXIS Pharmaceutical, Vaxdyn, ContraFect Corporation (CFRX), Debiopharm, Idorsia, Telum Therapeutics, Bioharmony Therapeutics, Destiny Pharma, BioVersys, Hoffmann-La Roche, SuperTrans Medical, Agile Biotics, Qpex Biopharma, Antabio, Nosopharm, Aridis Pharmaceuticals, Brii Biosciences, and others.
  • Key Acinetobacter Infections Pipeline Therapies: Sulbactam-durlobactam, SPR206, OMN 7, ESKAPE Pathogens bacteriophages, TP-102, VNRX-5113, VXD-001, Debio1454, TP-6076, BH02, XF-73, BV100, AcinetoVax, RG6006, ​OMNIvance, PBP inhibitors, NOSO-2G, AR-401,  BRII-693, and others.

Dive deep into rich insights for drugs for Acinetobacter infections treatment; visit @ Acinetobacter Infections Treatment 

Table of Contents

1. Acinetobacter Infections Pipeline Report Introduction
2. Acinetobacter Infections Pipeline Report Executive Summary
3. Acinetobacter Infections Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Acinetobacter Infections Pipeline Therapeutics
6. Acinetobacter Infections Pipeline: Late Stage Products (Pre-registration)
6.1 Sulbactam-durlobactam: Entasis Therapeutics
7. Acinetobacter Infections Pipeline: Late Stage Products (Preregistration)
8. Acinetobacter Infections Pipeline: Mid Stage Products (Phase II)
9. Acinetobacter Infections Pipeline: Early Stage Products (Phase I)
9.1 OMNIvance: Qpex Biopharma
10. Acinetobacter Infections Pipeline Therapeutics Assessment
11. Inactive Products in the Acinetobacter Infections Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the Acinetobacter Infections Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

For further information on the Acinetobacter infections pipeline therapeutics, reach out @ Best Therapy for Acinetobacter Infections

Related Reports

Acinetobacter Infections Epidemiology

Acinetobacter Infections Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Acinetobacter infections epidemiology in the 7MM.

Multidrug-Resistant Acinetobacter Infections Market

Multidrug-Resistant Acinetobacter Infections Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted multidrug-resistant Acinetobacter infections epidemiology in the 7MM.

Multidrug-Resistant Acinetobacter Infections Pipeline

Multidrug-Resistant Acinetobacter Infections Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key multidrug-resistant Acinetobacter infections companies, including  Wockhardt, Tetraphase Pharmaceuticals, Geom Therapeutics, Atterx Biotherapeutics, Hsiri Therapeutics, Antabio, TAXIS Pharmaceutical, Vaxdyn, ContraFect Corporation (CFRX), Debiopharm, among others.

Clostridium difficile Infection Pipeline

Clostridium difficile Infection Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key Clostridium difficile infection companies, including Crestone, MicroPharm Ltd., SAb Biotherapeutics, Ferring Pharmaceuticals, Seres Therapeutics, Nestlé Health Science, Finch Therapeutics, among others.

Bacteremia Market

Bacteremia Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key bacteremia companies, including Armata Pharmaceuticals, Contrafect, Basilea Pharmaceutical, among others.

Staphylococcus aureus Bacteremia Market

Staphylococcus aureus Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key Staphylococcus aureus companies, including ContraFect, XBiotech, Genentech, Durata Therapeutics, among others.

Other Trending Reports

Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. 

Connect with us at LinkedIn 


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

ICIS announces the 16th Asian Base Oils and Lubricants Conference in Singapore

Published

on

icis-announces-the-16th-asian-base-oils-and-lubricants-conference-in-singapore

LONDON, May 20, 2024 /PRNewswire/ — ICIS, a global source of commodity intelligence, has announced the 16th Asian Base Oils and Lubricants Conference will take place in Singapore, 27-28 June 2024. The event offers a platform for senior executives to connect with peers, potential clients and industry leaders, offering insight into the latest trends, innovation and best practices within the industry.

Dr Sarawut Kaewtathip, Director General – Department of Mineral Fuels from the Ministry of Energy, Thailand will present a keynote delving into the Thai fuels and lubricants market. He will offer insight into growth opportunities within the automotive sector following COVID-19 and explain how the base oils and lubricants industry can support future developments.
The conference will also include exclusive market data from Michael Connolly, Principal Analyst, Refining at ICIS, who comments: “While Asian prices have been less impacted by global events than in other regions, it has still been affected, which is highlighted by further Group I closures in the region. This conference provides a vital platform to exchange knowledge and come together to learn collectively about the latest industry developments, whilst finding out how to best navigate uncertainty in the coming years.”
Delegates will also benefit from insight by Yan Chuang Zhao, Supervising Engineer of R&D Center at Great Wall Motors, who will be discussing ‘The wider Electric Vehicle picture in Asia’ and Charlotte Kehoe, AsPac Technology Director at bp Castrol who, who adds to the extensive line-up of speakers that conference attendees have come accustomed to. Charlotte will be looking to provide further insight into opportunities with data centres and immersion coolants across the region.
To find out more about the 16th ICIS Asian Base Oils and Lubricants Conference, or register for the event, please visit: https://events.icis.com/asian-base-oils/
About ICIS
ICIS – Independent Commodity Intelligence Services – helps businesses through seamlessly delivering data and analytics, across the chemical, and energy markets. A trusted source and benchmark for price information and insight across key commodities markets worldwide. Our independent, transparent market intelligence informs thousands of quality decisions every day, taking the pressure out of negotiations and giving customers space for more innovative thinking, through published datasets including price assessments, price forecasts, supply and demand fundamentals and more.
Over 150 years of shaping the world by connecting markets to optimise the world’s valuable resources. With a global team of more than 600 experts, ICIS has employees based in London, New York, Houston, Karlsruhe, Milan, Mumbai, Singapore, Guangzhou, Beijing, Shanghai, Dubai, Sao Paulo, Seoul, Tokyo and Perth.
ICIS is part of RELX, a FTSE15 company with a market cap of $78.2bn and an employee base of over 30,000 experts across 40 countries.
About RELX
RELX is a global provider of information and analytics for professional and business customers across industries. The Group serves customers in more than 180 countries and has offices in about 40 countries. It employs approximately 30,000 people of whom almost half are in North America. RELX PLC is a London listed holding company which owns 52.9% of RELX Group. RELX NV is an Amsterdam listed holding company which owns 47.1% of RELX Group. The shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX and RENX. Total market capitalisation is approximately £64.7bn |  €75.5bn |  $81.9bn.
Logo – https://mma.prnewswire.com/media/619935/4713254/ICIS_Logo.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/icis-announces-the-16th-asian-base-oils-and-lubricants-conference-in-singapore-302149492.html

Continue Reading

Artificial Intelligence

Subang Jaya Medical Centre Applauded by Frost & Sullivan as the Best Hospital Company of the Year in Malaysia for the fourth consecutive year

Published

on

subang-jaya-medical-centre-applauded-by-frost-&-sullivan-as-the-best-hospital-company-of-the-year-in-malaysia-for-the-fourth-consecutive-year

SJMC’s significant efforts in alleviating nursing shortages, enhancing workflows and its strong market-leading position, both locally and globally resulted in high patient retention and strong referrals.
SAN ANTONIO, May 20, 2024 /PRNewswire/ — Frost & Sullivan recently analyzed the hospital industry and noted that operational inefficiencies, workflow interruptions and shortage of skilled healthcare professionals are some key challenges faced by the healthcare industry. Based on its findings, Subang Jaya Medical Centre (SJMC) is recognized with the 2024 Malaysian Best Hospital Company of the Year Award for the fourth consecutive year in the hospitals industry, making it the first to be recognized continuously with this prestigious accolades

The company is a private hospital with 443 licensed beds and over 150 outpatient clinics. It handles approximately 50,000 admissions and 550,000 outpatient visits annually. With a workforce of around 1,600 healthcare professionals, SJMC offers services across more than 260 medical specialties encompassing diverse therapeutic areas such as oncology, cardiology, orthopedics, digestive health as well as women and children health.
Bhaskar Vittal, industry principal at Frost & Sullivan, observed, “SJMC provides comprehensive and integrated care, implementing practices aimed at achieving the best possible outcomes for patients. A typical cancer patient journey at SJMC starts with awareness-building and screening programs, continuing with diagnosis, treatment, and aftercare, which includes support groups, educators, and counselors—all key elements in cancer care management.
SJMC is a finalist flagship medical tourism hospital selected by the Malaysian Healthcare Travel Council (MHTC) which is fully endorsed by the Malaysian Ministry of Health. It has achieved several accreditations including the Joint Commission International (JCI) Accreditation and aims at providing patients a seamless transition throughout their health journey in Malaysia. Patient onboarding follows a process-oriented approach from the inquiry level, where patients receive detailed information on available services, specialist doctors, and treatment availability.
SJMC has achieved international branding and recognition for its Cancer & Radiosurgery Centre (CRC), known for its person-centered care approach. Moreover, the hospital has been credited by the Australian Council on Healthcare Standards International (ACHSI) as the first Center of Excellence (CoE) for oncology services in Asia-Pacific, marking a milestone achievement. SJMC continuously improves patient treatment options, expands day care surgical offerings, and prioritizes safety, faster recovery, and lower costs in line with industry trends to achieve medical excellence.
The hospital’s Genetic Wellness, a first-of-its-kind clinical-grade genetics testing program, provides more than 1,000 insights into patients’ health conditions based on their unique genetic blueprint. The test provides individualized information on a wide range of conditions, including chronic, infectious, and metabolic diseases, allergies, and drug responses, allowing individuals to make informed choices for their overall wellbeing.
SJMC became the first hospital in Malaysia to introduce a remote patient monitoring system, SeniorConnect, that is tailored to the unique needs of senior patients and is particularly beneficial in urban settings, where it is common for working adults to face challenges in caring for their elderly relatives. It is also the first hospital in Malaysia to perform day care robotic-assisted total knee replacement and total hip replacement procedures using the Mako SmartRobotics system. It also focuses on preventive and precision healthcare—key trends in the global healthcare industry.
Its continuous glucose monitoring (CGM) technology allows diabetes patients to continuously monitor and control their blood glucose. SJMC also successfully conducted a clinical improvement project, titled “Reducing Early Morning In-Patient Hypoglycemia Incidence among In-Patient Adults with Type 2 Diabetes Mellitus in non-Critical Care Wards,” which found that patients adhering to the recommended snack regimen experienced zero hypoglycemic incidents. SJMC aims to enhance diabetes wellness with its multidisciplinary approach through revolutionary technology and in-depth research.
SJMC’s artificial intelligence (AI)-powered Radixact X9 with Synchrony synchronizes the movement of radiation beams with the tumor’s motion, allowing seamless and continuous radiation delivery during the patient’s natural breathing patterns. This technology enables delivering accurate radiation dosage while minimizing exposure to healthy tissues.
“SJMC’s digital technologies and equipment enhance the patient journey, improve clinical outcomes, and provide the healthcare workforce with the best tools to achieve their medical excellence goals,” added Vittal.
Bryan Lin, Chief Executive Officer of SJMC expressed his gratitude for receiving this prestigious recognition for the fourth time, saying, “We’re honored to be recognized for the exceptional care our dedicated staff provides. Their unwavering commitment and teamwork are what truly make a difference for our patients. We’ll continue to pursue excellence and deliver world-class healthcare.”
“In today’s healthcare landscape, strengthening the healthcare workforce, enhancing workflows, and solidifying our market-leading position are paramount. We’re committed to achieving these goals by empowering our staff through training which improves the quality of patient care and equipping them with tools that enhance decision-making while encouraging them to embrace and learn in this digital healthcare era,” he adds.
With its excellent financial performance, seamless customer experiences, and strong overall performance, Subang Jaya Medical Centre’s unwavering dedication to exceptional healthcare is again recognized on the international stage, with their fourth consecutive award win.
Each year, Frost & Sullivan presents a Company of the Year award to the organization that demonstrates excellence in terms of growth strategy and implementation in its field. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration.
Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.
About Frost & SullivanFor six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.
Contact:Tarini SinghP: +91-9953764546E:[email protected]
About SJMC
Subang Jaya Medical Centre (SJMC)
SJMC has an impeccable reputation as one of Malaysia’s most trusted private medical centres best known for its clinical outcomes. The hospital is an award-winning 443-bed multi-disciplinary tertiary hospital of CAH Medical Centres (previously known as Ramsay Sime Darby Health Care Group), providing comprehensive and complex care in all specialties.
It is one of the few internationally accredited Joint Commission International (JCI) hospitals in Malaysia and Malaysian Society for Quality in Health (MSQH) accredited. SJMC’s laboratory is also an internationally recognized MS ISO 15189 accredited since 2009. In 2023, SJMC Oncology (Cancer) Services is certified by Australian Council of Healthcare Standards (ACHS) International as a Centre of Excellence, making it the first in Asia-Pacific.
SJMC is recognized as a finalist for the Flagship Medical Tourism Hospital Programme 2023 – 2025 by Malaysia Healthcare Travel Council (MHTC) to establish Malaysia as a globally renowned icon for healthcare travel, delivering exceptional end-to-end patient experiences anchored on medical excellence, service excellence, and international branding. It receives both local patients across Malaysia and international patients across the Asia Pacific with over 47,000 admissions and almost half a million outpatient visits annually.
For more information, contact:Celia TanP: +60 17 930 8200E: [email protected] 
Nur Yee Jie MinP: +012 355 1885E: [email protected] 
Photo – https://mma.prnewswire.com/media/2415752/SJMC_Award.jpg

View original content:https://www.prnewswire.co.uk/news-releases/subang-jaya-medical-centre-applauded-by-frost–sullivan-as-the-best-hospital-company-of-the-year-in-malaysia-for-the-fourth-consecutive-year-302148854.html

Continue Reading

Artificial Intelligence

More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024

Published

on

more-than-$9-million-awarded-to-high-school-scientists-and-engineers-at-the-regeneron-international-science-and-engineering-fair-2024

Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world’s largest pre-college science, technology, engineering and math (STEM) competition.
TARRYTOWN, N.Y. and WASHINGTON, May 17, 2024 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Grace Sun, 16, of Lexington, Kentucky, won the $75,000 top award, the George D. Yancopoulos Innovator Award, named in honor of the pioneering drug researcher and Regeneron co-Founder, Board co-Chair, President and Chief Scientific Officer, in the 2024 Regeneron International Science and Engineering Fair (Regeneron ISEF), the world’s largest pre-college science and engineering competition. Other top prizes went to projects in second-order cone programming, microplastics filtration and multi-sensory therapy for dementia.

The top winners were honored during two award ceremonies: the Special Awards on May 16 and the Grand Awards Ceremony on the morning of May 17. In total, over $9 million USD was awarded to the finalists based on their projects’ creativity, innovation and depth of scientific inquiry. The competition featured nearly 2,000 young scientists representing 49 U.S. states and nearly 70 countries, regions and territories across the world.
Grace Sun, 16, of Lexington, Kentucky, won first place and received the $75,000 George D. Yancopoulos Innovator Award for her research on building a better organic electrochemical transistor that she hopes will be used to develop new electronic devices that could help detect and treat serious illnesses like diabetes, epilepsy and organ failure. To overcome the problems that have previously prevented such devices from working effectively inside the body, Grace developed a new way of chemically treating their organic components, which greatly improved their laboratory performance.
Michelle Wei, 17, of San Jose, California, received one of two Regeneron Young Scientist Awards of $50,000 for her research to improve the speed and efficiency of a type of software that is useful in many fields such as machine learning, transportation and financial systems. Michelle’s new approach involved determining a quick approximate solution to the second-order cone programming problem, then splitting the initial cone into smaller cones, which enabled her new algorithm to greatly outperform previous approaches.
Krish Pai, 17, of Del Mar, California, received the second Regeneron Young Scientist Award of $50,000 for his machine-learning research to identify microbial genetic sequences that can be modified to biodegrade plastic. His new software, called Microby, scans databases of microorganisms and determines which ones can be changed genetically to biodegrade plastics. In tests, he identified two microorganisms that can be genetically modified to degrade plastic at a cost he believes would be ten times less than traditional recycling.
 “Congratulations to the Regeneron International Science and Engineering Fair 2024 winners,” said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News. “I’m truly inspired by the ingenuity and determination shown by these remarkable students. Coming from around the world with diverse backgrounds and academic disciplines, these students have shown that it is possible to come together in unity to tackle some of the toughest challenges facing our world today, and I could not be prouder.”
Regeneron ISEF provides a global stage for the world’s best and brightest young scientists and engineers. Through this competition, Regeneron and the Society are fostering the next generation of STEM leaders who are pioneering solutions to improve our world. Since 2020, Regeneron has provided STEM experiences to approximately 2.4 million students, on track to meet its goal of 2.5 million by 2025.
“The talent, intelligence and potential of this year’s Regeneron ISEF finalists is truly inspiring, and I congratulate each on their remarkable achievements,” said George D. Yancopoulos, M.D., Ph.D., co-Founder, Board co-Chair, President and Chief Scientific Officer of Regeneron. “Science competitions like ISEF were pivotal in shaping my own career and fueling my passion to fight back against disease. I look forward to seeing these students continue to push the boundaries of science and technology to create positive and sustainable change for all humanity.”
Other top honors from the competition include:
Justin Huang and Victoria Ou, both 17, of Woodlands, Texas, received the Gordon E. Moore Award for Positive Outcomes for Future Generations of $50,000 for their new prototype filtration system that uses ultrasonic waves to remove microscopic plastic particles from water. In lab tests, the acoustic force from the high-frequency sound waves removed between 84% and 94% of the suspended microplastic particles in a single pass. The students are now working to scale up and fine-tune their experimental system.
Ingrid Wai Hin Chan, 17, of Hong Kong, China received the Craig R. Barrett Award for Innovation of $10,000 for her research on using a multi-sensory therapy for dementia patients. Her mixed therapy app would allow patients to practice physical and cognitive skills through a personalized, immersive environment using virtual reality headsets. Ingrid conducted an eight-week study with six people living with dementia and found that the cognitive function of patients who used her prototype improved in several areas. She believes her app could serve as a viable option for dementia patients with limited access to in-person professional therapy.
Tanishka Balaji Aglave, 15, of Valrico, Florida, received the H. Robert Horvitz Prize for Fundamental Research of $10,000 for her investigation into a natural alternative treatment against citrus greening, a disease that threatens citrus farming in many parts of the world and is currently only treated with antibiotics. Tanishka injected the trunks of infected trees with an extract from the curry leaf tree, and found through tests that this potential method could effectively and sustainably manage citrus greening disease.
Maddux Alexander Springer, 18, of Honolulu, Hawaii, received the Peggy Scripps Award for Science Communication of $10,000 for his research into fibropapillomatosis (FP), a disease that is the primary cause of death in green sea turtles. Some turtles he studied in Kaneohe Bay, Hawaii, were stricken with a disease that causes internal and external tumors that inhibit their everyday lives. After analyzing the turtles’ diet of green algae, Maddux concluded that this disease, wastewater, invasive algae and the amino acid arginine all pose a grave risk to these endangered sea creatures.
Ria Kamat, 17, of Hackensack, New Jersey; Anna Oliva, 17, of Houston, TX; and Shuhan Luo, 18, of Worcester, MA, received the Dudley R. Herschbach SIYSS Award, which provides finalists an all-expense paid trip to attend the Stockholm International Youth Science Seminar during Nobel Week in Stockholm, Sweden.
Jack Shannon, 18, of Clane, Kildare, Ireland, and Nikhil Vemuri, 17, of Cary, North Carolina, received the EU Contest for Young Scientists Award. Their projects will represent Regeneron ISEF at the EU Contest for Young Scientists to be held this September in Katowice, Poland.
For more information about the top winners and access to visual assets visit:  https://www.societyforscience.org/isef-2024-media-kit.
The full list of Special Award ISEF 2024 Finalists can be found at https://www.societyforscience.org/press-release/regeneron-isef-2024-special-awards-winners.
In addition to the Top Award winners, more than 450 finalists received awards and prizes for their innovative research, including “First Award” winners, who each received a $5,000 prize.
The following lists the First Award winners for each of the 22 categories, from which the Top Awards were chosen:
Animal Sciences, sponsored by Society for ScienceMaddux Alexander Springer, Honolulu, Hawaii
Behavioral and Social Sciences, sponsored by Society for ScienceAndrew Y. Liang, San Jose, California
Biochemistry, sponsored by RegeneronAmy Hong Xiao, Garden City, New York
Biomedical and Health Sciences, sponsored by RegeneronRia Kamat, Hackensack, New Jersey; Kevin Xuan Lei, Shanghai, China
Biomedical Engineering, sponsored by Alfred E. Mann CharitiesAyush Garg, Dublin, California; Divij Motwani, Palo Alto, California; Akash Ashish Pai, Portland, Oregon
Cellular and Molecular Biology, sponsored by RegeneronLara and Maya Sarah Hammoud, Beverly Hills, Michigan
Chemistry, sponsored by Society for ScienceAkilan Sankaran, Albuquerque, New Mexico; Arjun Suresh Malpani and Siddharth Daniel D’costa, Portland, Oregon
Computational Biology and Bioinformatics, sponsored by RegeneronKun-Hyung Roh, Bronx, New York
Earth and Environmental Sciences, sponsored by Google.orgNikhil Vemuri, Durham, North Carolina; Justin Yizhou Huang and Victoria Ou, The Woodlands, Texas
Embedded Systems, sponsored by HPChloe Rae and Sophie Rose Filion, Welland, Ontario, Canada
Energy: Sustainable Materials and Design, sponsored by Siemens EnergyAlia Wahban, Hamilton, Ontario, Canada
Engineering Technology: Statics and Dynamics, sponsored by Howmet Aerospace FoundationChiyo Nakatsuji, Bunkyoku, Tokyo, Japan; Kevin Shen, Olympia, Washington
Environmental Engineering, sponsored by JacobsKrish Pai, San Diego, California; Jack Shannon, Clane, Kildare, Ireland
Materials Science, sponsored by Howmet Aerospace FoundationGrace Sun, Lexington, Kentucky
Mathematics, sponsored by Akamai FoundationAnna Oliva, Houston, Texas
Microbiology, sponsored by Schattner FoundationMatthew Chang, Irvine, California
Physics and Astronomy, sponsored by Richard F. Caris Charitable Trust IIHarini Thiagarajan and Vishal Ranganath Yalla, Bothell, Washington; Shuhan Luo, Worcester, Massachusetts
Plant Sciences, sponsored by Society for SciencePauline Estrada, Fresno, California; Tanishka Balaji Aglave, Dover, Florida
Robotics and Intelligent Machines, sponsored by RegeneronMichal Lajciak, Dubnica nad Vahom, Trenciansky kraj, Slovakia; Anthony Efthimiadis, Oakville, Ontario, Canada
Systems Software, sponsored by MicrosoftMichelle Wei, San Jose, California
Technology Enhances the Arts, sponsored by Society for ScienceAnant Khandelwal, Sritan Motati and Siddhant Sood, Alexandria, Virginia
Translational Medical Science, sponsored by RegeneronZheng-Chi Lee, West Lafayette, Indiana; Ingrid Wai Hin Chan, Hong Kong, China
The full list of all award-winning ISEF 2024 finalists is available here: https://www.societyforscience.org/press-release/regeneron-isef-2024-full-awards.
View all the finalists’ research here: https://projectboard.world/isef.
About the Regeneron International Science and Engineering FairThe Regeneron International Science and Engineering Fair (Regeneron ISEF), a program of Society for Science for over 70 years, is the world’s largest global science competition for high school students. Through a global network of local, regional and national science fairs, millions of students are encouraged to explore their passion for scientific inquiry. Each spring, a group of these students is selected as finalists and offered the opportunity to compete for approximately U.S. $9 million in awards and scholarships.
In 2019, Regeneron became the title sponsor of ISEF to help reward and celebrate the best and brightest young minds globally and encourage them to pursue careers in STEM to positively impact the world. Regeneron ISEF is supported by a community of additional sponsors, including Akamai Foundation, Alfred E. Mann Charities, Aramco, Caltech, Google.org, Gordon and Betty Moore Foundation, Howmet Aerospace Foundation, HP, , Jacobs, King Abdulaziz & his Companions Foundation for Giftedness and Creativity, Microsoft, National Geographic Society, Richard F. Caris Charitable Trust II, Rise, an initiative of Schmidt Futures and the Rhodes Trust, Schattner Foundation, Siemens Energy, Annenburg Foundation, Ballmer Group, Broadcom Foundation, Cesco Linguistic Services, Conrad N. Hilton Foundation, Edison International, Insaco, Oracle Academy, The Eli and Edythe Broad Foundation, The Ralph M. Parsons Foundation and US Army ROTC. Many are entrepreneurs across a wide range of industries. Learn more at https://www.societyforscience.org/isef/.
About Society for ScienceSociety for Science is a champion for science, dedicated to promoting the understanding and appreciation of science and the vital role it plays in human advancement. Established in 1921, Society for Science is best known for its award-winning journalism through Science News and Science News Explores, its world-class science research competitions for students, including the Regeneron Science Talent Search, the Regeneron International Science and Engineering Fair and the Thermo Fisher Scientific Junior Innovators Challenge, and its outreach and equity programming that seeks to ensure that all students have an opportunity to pursue a career in STEM. A 501(c)(3) membership organization, Society for Science is committed to inform, educate and inspire. Learn more at www.societyforscience.org and follow us on Facebook, Twitter, Instagram and Snapchat (Society4Science).
About RegeneronRegeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases. 
Regeneron believes that operating as a good corporate citizen is crucial to delivering on our mission. We approach corporate responsibility with three goals in mind: to improve the lives of people with serious diseases, to foster a culture of integrity and excellence and to build sustainable communities. Regeneron is proud to be included on the Dow Jones Sustainability World Index and the Civic 50 list of the most “community-minded” companies in the U.S. Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro bono and matching gift programs. Our most significant philanthropic commitments are in the area of early science education, including the Regeneron Science Talent Search and the Regeneron International Science and Engineering Fair (ISEF).
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
More information about the top winners and access to visual assets visit:  https://www.societyforscience.org/isef-2024-media-kit.
Media ContactsJoseph Brown, [email protected]
Gayle Kansagor, Society for [email protected]
Photo – https://mma.prnewswire.com/media/2416174/Regeneron_ISEF_2024_Winners_Photo.jpg 
Logo – https://mma.prnewswire.com/media/2416197/Society_for_Science_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/more-than-9-million-awarded-to-high-school-scientists-and-engineers-at-the-regeneron-international-science-and-engineering-fair-2024-302149316.html

Continue Reading

Trending